The increase in demand is a combination of organic growth and impact from the COVID-19 situation where individual customers have placed stock-orders to ensure they have product in case of disruption in supply. Due to the uncertainty related to the situation in the world markets we are not updating the general revenue guiding for the year at this stage and will come back to more information related to the outlook for 2020 in the Q1-2020 earnings release that will be held on May 6[th]. Although we have planned to host face to face presentations going forward, this earnings release will be held as a web-conference due to the ongoing COVID-19 situation.
During the unprecedented situation the world now is going through we want to provide an update on what the
Further, in the finalization of the 2019 Annual Accounts, due to be released on April 30[th], the company has late March received a notice from the
This change in ruling from the US CBP will have a future effect on import to the US of formulated products, however, due to more production now taking place locally in the US, the impact to the gross margin is limited, and is on an annual basis for 2020 estimated to be between 0,5% and 1,5% of total sales. Due to this limited impact we are not at this stage changing our guiding on Gross Margin for the year and maintain the expectation to be between 42% and 47% as earlier communicated.
For more information, please contact:
Kjetil Ramsøy, CEO,
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
https://news.cision.com/nattopharma-asa/r/doubled-revenue-in-q1---demonstrated-scalability,c3081825
https://mb.cision.com/Main/2037/3081825/1224790.pdf
https://mb.cision.com/Public/2037/3081825/b81bf157a90e05d0.pdf
(c) 2020 Cision. All rights reserved., source